HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Janssen Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Janssen Intelligence Report

Generated from 14 signals · 6 evidence sources

Type

Company Intelligence Report

Generated

Jun 21, 2026

Confidence

Moderate Confidence · 68%

Evidence

76 items

Sources

31

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Janssen maintains an active intelligence profile across Oncology, Monoclonal Antibody, Neurology, Opioid Overdose, Antiepileptic. 14 signals are linked with 2 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 68% across 6 tracked sources. Highest-priority development: Regulatory Developments Reshaping Competitive Landscape in Neurology Markets. Portfolio development. Regulatory Developments Reshaping Competitive Landscape in Neurology Markets is an owned Janssen portfolio development in Neurology · Depression.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. investigateJun 16, 2026

    Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis

    Neurology · Alzheimer's Disease · opportunity score 68

    View detail
  2. investigateJun 20, 2026

    FDA Approves OTC Naloxone Nasal Spray Rextovy for Opioid Overdose

    Neurology · Opioid Overdose · opportunity score 63

    View detail
  3. regulatory

    FDA AP — LAZCLUZE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  4. regulatory

    FDA AP — TECVAYLI (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  5. regulatory

    FDA AP — TREMFYA (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    FDA AP — DARZALEX (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    FDA AP — DARZALEX (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    FDA AP — BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer

    Regulatory precedent may inform portfolio positioning

    View detail
  11. regulatory

    FDA AP — REXTOVY (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  12. regulatory

    FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney Injury

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 824 with buyer quality 6 (Emerging). Competitive pressure: Low. Portfolio impact: High. 2 investigate-priority signals warrant near-term portfolio review.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • FDA AP — LAZCLUZE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — TECVAYLI (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — TREMFYA (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — DARZALEX (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — DARZALEX (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (SUPPL)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — REXTOVY (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney Injury

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — ARGATROBAN IN SODIUM CHLORIDE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — DIVALPROEX SODIUM (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — DIVALPROEX SODIUM (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — DIVALPROEX SODIUM (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — DIVALPROEX SODIUM (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney Injury

    High Confidence · 95%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis

    Neurology · Alzheimer's Disease

  • FDA Approves OTC Naloxone Nasal Spray Rextovy for Opioid Overdose

    Neurology · Opioid Overdose

  • Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Detection

    Neurology · Alzheimer's Disease

  • FDA Approves Supplemental Application for REXTOVY by Amphastar Pharmaceuticals

    Neurology · Opioid Overdose

  • FDA Approves Supplement for Levetiracetam by Chartwell RX

    Neurology · Antiepileptic

  • TARO's ANDA219052 for PERAMPANEL Receives Approval Status

    Neurology · Anticonvulsant

  • FDA Accepts Supplement for SPRAVATO (Esketamine Hydrochloride)

    Neurology · Depression

  • FDA Accepts Supplement Application for DARZALEX by Janssen Biotech

    Oncology · Monoclonal Antibody

Assets

  • Regulatory Developments Reshaping Competitive Landscape in Neurology Markets

    Portfolio asset

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.